Eric Lefkofsky: The Man Trying to Cure Cancer

Technology has helped many industries make enormous bounds, and health care is no exception. For example, consider appendicitis. Today, an appendectomy is a routine procedure. But in years past, a burst appendix was a death sentence. Across the entire realm of healthcare, technology makes doctors better. However, despite the great leaps that healthcare has taken since the advancement of computers, modern healthcare still has one major flaw, according to Eric Lefkofsky: cancer treatment.

If you’ve been to the doctor recently, then you probably noticed the data collection that happens during a visit. The front desk always gets your information, and the nurse and doctor both take meticulous, detailed notes about the nature of your health. With such an abundance of information being collected, Eric Lefkofsky was shocked to see that cancer treatment was so far behind. Even with the massive data collection now possible, he sensed potential for improvement in treating cancer. Most importantly, though, he decided to do something about it. By co-starting Tempus, a startup dedicated to curing cancer, Lefkofsky is of the disease’s most staunch adversaries and more information click here.

Lefkofsky’s motivation is clear. The idea of starting Tempus sparked during his wife’s run-in with breast cancer. When Lefkofsky realized the inadequacy of cancer care, and how much it could be improved through technology, he decided to take action. Fighting cancer is a noble cause, and Lefkofsky directing his efforts towards it shows the type of person that he is. The creation of Tempus also showcases Lefkofsky’s genius. The company’s mission is valid, but difficult. Still, they have been successful to this point; Tempus created a new and more efficient way to collect data on cancer patients. It’s surprising that such a feat wasn’t yet accomplished, but thankfully, Lefkofsky stepped in as the pioneer of this new technology and learn more about Eric.

Tempus is likely the most significant milestone in Lefkofsky’s career, but he’s spend large parts of his life in other pursuits as well. He is also a co-partner of Lightbank, a venture fund. Along with this, he’s held influential roles in a number of other companies: Echo Global Logistics, Mediaocean, and Innerworkings to name several. At this point, there’s no telling where Lefkofsky will go next. But right now, his current target is cancer. From what we know about Lefkofsky, he won’t stop until the job is finished and Eric on Facebook.

More Visit: http://www.chicagobusiness.com/article/20161001/ISSUE01/310019995/can-eric-lefkofsky-save-your-life

Eric Lefkofsky Seeks to Revolutionize Cancer Treatment with Tempus

Approximately 40% of American adults will face having cancer according to statistics. This terrible condition has been on the rise and by 2024, it could reach nearly 20 million American adults. Fortunately, medicine is advancing and Tempus and other companies are investing in the treatment of cancer and making survival more attainable with data-enabled precision medicine. Tempus is led by Eric Lefkofsky who is one of the co-founders.

Electronic health records (EHRs) have come into mainstream usage and should help further the use of technology in medicine. Contrary to expectations, huge amounts of data are collected but still not made available to health professionals in a standard way, which could save time and lives in the treatment of cancer and other diseases.

Tempus has the goal of transforming the way cancer care is done. The platform Tempus is developing should be able to analyze the clinical and molecular data of a patient. Tempus is able to develop the software for this, but obtaining medical data was an initial obstacle. In cancer treatment, much data that is collected by physicians is not structured into data, but with Tempus’ optical recognition capabilities and natural language processing software, the data collected in the progression of patients could be put to use to improve their treatment of cancer.

Tempus is also working on molecular data that would include genomic information from the human genome sequencing project. The cost of genome sequencing of an individual is affordable but still not very cheap. Tempus expects to be able to help the price of human genome sequencing become even more affordable. Tempus has the objective of combining molecular information, clinical data from patients and genome sequencing to make fighting diseases not only a reactive and possibly avoiding repetitive unnecessary testing in fighting against cancer as well as other diseases and learn more about Eric Lefkofsky.

Eric Lefkofsky is from Southfield, Michigan. He holds a Juris Doctor degree from the University of Michigan. Lefkofsky is considered a power player in the IT and dot-com areas and more information click here.

Currently, Lefkofsky is on the board of directors at Lurie’s Children’s Memorial Hospital, as well as the Art Institute of Chicago. In the same area of art, Lefkofsky is also a board trustee and chairman of Chicago’s Steppenwolf Theatre Company. Eric Lefkofsky has taught at DePaul University’s Kellstadt Graduate School of Business and also at Northwestern University’s Kellogg School of Management. Lefkofsky now teaches at the University of Chicago’s Booth School of Business and Eric Lefkofsky’s lacrosse camp.